Experimental and Molecular Medicine

Korean Society for Biochemistry and Molecular Biongy (생화학분자생물학회)
권호 표지

Trichostatin A-mediated upregulation of p21$^{WAF1}$ contributes to osteoclast apoptosis

Yi, Tac-Ghee;Baek, Jeong-Hwa;Kim, Hye-Jin;Choi, Mi-Hye;Seo, Sang-Beom;Ryoo, Hyun-Mo;Kim, Gwan-Shik;Woo, Kyung-Mi

  • Published : 20070400
⟨ Previous Next ⟩

Abstract

Histone deacetylase inhibitors (HDIs), a new class of anti-cancer agents, have been reported to suppress formation of osteoclast precursors and their fusion into multinucleated cells. However, little is known about the effect of HDIs on mature osteoclasts, which may have significance for their therapeutic use. Here, we demonstrate a novel action of HDIs on osteoclast apoptosis. Primary multinucleated mature osteo - clasts were prepared from mouse bone marrow cells. Treatment of osteoclasts with the HDI trichostatin A (TSA) caused apoptosis, as confirmed by annexin V staining and caspase activation. TSA caused the upregulation of p21 WAF1 in osteoclasts. To understand the role of p21WAF1 upregulation in TSA-treated osteoclasts, shRNA against p21WAF1-containing lentivirus was introduced into osteoclasts. The suppression of p21WAF1 decreased TSA-directed osteoclast apoptosis. Collectively, our results pro - vide evidence that TSA causes osteoclast apoptosis, which involves, in part, TSA-induced upregulation of p21 WAF1 , and strongly supports HDIs as potential therapeutic agents for excessive bone resorption.

Keywords

References

  1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42 https://doi.org/10.1038/nature01658
  2. Burgess AJ, Pavey S, Warrener R, Hunter LJ, Piva TJ, Musgrove EA, Saunders N, Parsons PG, Gabrielli BG. Up-regulation of p21 (WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol 2001;60: 828-37
  3. Chopin V, Slomianny C, Hondermarck H, Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21 (waf1). Exp Cell Res 2004;298:560-73 https://doi.org/10.1016/j.yexcr.2004.04.038
  4. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003;13:65-70 https://doi.org/10.1016/S0962-8924(02)00043-0
  5. Fuller K, Lean JM, Bayley KE, Wani MR, Chambers TJ. A role for TGFbeta (1) in osteoclast differentiation and survival. J Cell Sci 2000;113:2445-53
  6. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-49
  7. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004;101:1241-6 https://doi.org/10.1073/pnas.0307708100
  8. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996;2:1132-6 https://doi.org/10.1038/nm1096-1132
  9. Jeon EJ, Lee KY, Choi NS, Lee MH, Kim HN, Jin YH, Ryoo HM, Choi JY, Yoshida M, Nishino N, Oh BC, Lee KS, Lee YH, Bae SC. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem 2006;281:16502-11 https://doi.org/10.1074/jbc.M512494200
  10. Kim HJ, Chang EJ, Kim HM, Lee SB, Kim HD, Kim SG, Kim HH. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha. Free Radic Biol Med 2006;40:1483-93 https://doi.org/10.1016/j.freeradbiomed.2005.10.066
  11. Liu S, Bishop WR, Liu M. Differential effects of cell cycle regulatory protein p21 (WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 2003; 6:183-95 https://doi.org/10.1016/S1368-7646(03)00044-X
  12. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-78 https://doi.org/10.1359/jbmr.1998.13.11.1668
  13. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6 https://doi.org/10.1093/jnci/92.15.1210
  14. Nakamura T, Kukita T, Shobuike T, Nagata K, Wu Z, Ogawa K, Hotokebuchi T, Kohashi O, Kukita A. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 2005; 175:5809-16 https://doi.org/10.4049/jimmunol.175.9.5809
  15. Okahashi N, Murase Y, Koseki T, Sato T, Yamato K, Nishihara T. Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21 (WAF1/CIP1) and p27 (KIP1). J Cell Biochem 2001;80: 339-45 https://doi.org/10.1002/1097-4644(20010301)80:3<339::AID-JCB60>3.0.CO;2-#
  16. Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004;10:2289-98 https://doi.org/10.2174/1381612043383980
  17. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 2003;101:3451-9 https://doi.org/10.1182/blood-2002-08-2622
  18. Sankar U, Patel K, Rosol TJ, Ostrowski MC. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1. J Bone Miner Res 2004;19:1339-48 https://doi.org/10.1359/JBMR.040321
  19. Schroeder TM, Westendorf JJ. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 2005;20:2254-63 https://doi.org/10.1359/JBMR.050813
  20. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000;108:153-64
  21. Wolffe AP, Hayes JJ. Chromatin disruption and modification. Nucleic Acids Res 1999;27:711-20 https://doi.org/10.1093/nar/27.3.711
  22. Yi T, Kim HJ, Cho JY, Woo KM, Ryoo HM, Kim GS, Baek JH. Tetraspanin CD9 regulates osteoclastogenesis via regulation of p44/42 MAPK activity. Biochem Biophys Res Commun 2006;347:178-84 https://doi.org/10.1016/j.bbrc.2006.06.061